References / Read a little further
What each NAD+ source helps explain
You don’t need to read every paper to follow the guide. If you want to check a claim, these are the sources behind the links. The notes explain what each adds, and where its answer stops.
Match the source to the question
A cell biology review can explain why researchers are interested in NAD+. A human trial can tell us what happened to the people enrolled. Neither answers every question about a particular compounded preparation.
For any health claim, look for the ingredient, route, participants and measured result. Keeping those together makes a source much more useful than its headline alone.
NAD+ and the work it does in cells
Covarrubias and colleagues · Nature Reviews Molecular Cell Biology · 2021
Explains how cells make, reuse and consume NAD+. Useful background for the molecule and its precursors, rather than evidence that a particular preparation improves someone’s health.
Oral NMN and muscle response to insulin
Yoshino and colleagues · Science · 2021
A trial in prediabetic, postmenopausal women. Muscle insulin sensitivity improved; body composition and HbA1c didn’t change. It didn’t test heart-attack prevention or compounded NAD+ injections.
Oral NR and whole-blood NAD+
Conze, Brenner and Kruger · Scientific Reports · 2019
Healthy overweight adults took oral NR for eight weeks. Whole-blood NAD+ rose, with larger increases at higher amounts. The study can’t settle safety over years or prove benefit in every organ.
What human precursor research has shown so far
Vinten and colleagues · Nature Metabolism · 2025
Reviews the human evidence, finding limited evidence of health benefits and little information from individual tissues. Helpful for seeing the gaps that a blood measurement or animal experiment can’t fill.
What changed during a six-hour NAD+ infusion
Human infusion pilot · Frontiers in Aging Neuroscience · 2019
A small study in healthy men, tracking NAD+ and related substances in blood and urine. It describes what happened during an infusion, rather than showing heart protection or an effective treatment schedule.
Intravenous NAD+ in a rat heart experiment
Zhang and colleagues · American Journal of Translational Research · 2016
Researchers interrupted and restored heart blood flow. NAD+ reduced the damaged area in that rat experiment. This is animal evidence, rather than proof of heart protection in people.
NMN in a mouse heart experiment
Yamamoto and colleagues · PLOS ONE · 2014
NMN reduced heart injury in a mouse model of interrupted and restored blood flow. It was injected into the abdominal cavity, which distinguishes it from oral human NMN research and intravenous NAD+.
What FDA means by compounding
U.S. Food and Drug Administration
Explains compounding and why compounded drugs are not FDA-approved. A useful starting point for the terminology, rather than a finding about a particular NAD+ preparation’s benefits.
FDA’s explanation of compounding risks
U.S. Food and Drug Administration
Covers contamination, incorrect strength and the lack of FDA checks for safety, effectiveness and quality before marketing. These are general risks, not a claim that a specific preparation is defective.
The law on patient-specific compounding
21 U.S.C. 353a · United States Code, reproduced by Cornell's Legal Information Institute
Covers compounding for identified patients based on valid prescriptions, with other conditions. Naming this framework doesn’t establish that a particular preparation meets every requirement.
The law on outsourcing facilities
21 U.S.C. 353b · United States Code, reproduced by Cornell's Legal Information Institute
Sets out a different framework for facilities that register with FDA. Compounded medicines are not FDA-approved, and registration doesn’t establish a benefit for a proposed use.
Keep reading by route: the molecule, oral study amounts, or injectable preparations.